Gastrointestinal therapies · Rare-disease therapies · Pharmaceuticals
Takeda Pharmaceutical
Japan's largest pharmaceutical company, developing gastrointestinal and rare-disease treatments. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
4502.T Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-09-04'21-5.8%'22+29.2%'23+11.1%'24+0.9%'25+30.2%YTD+11.7%
Money in ▸·
Takeda Pharmaceutical~¥4.5T
▸ Money out·
Financials & Segments
- Total revenue · ~¥4.5T (FY2024)
- Segments · Pharmaceuticals
Revenue from
No refined links yet.
Pays to
No refined links yet.